AbbVie has achieved a significant regulatory victory in the oncology space. Over the past weekend, the U.S. Food and Drug Administration (FDA) approved a novel combination therapy that promises to simplify treatment for specific blood cancer patients. This development has prompted several market analysts to revise their outlook for the pharmaceutical giant upward.
Market Analysts React Positively
The immediate response from the financial community was notably bullish. On February 21, investment bank Barclays upgraded AbbVie’s stock to a “Strong-Buy” rating, simultaneously setting a new price target of $275 per share. This move reflects recognition of the company’s strategic strengthening of its oncology division, a segment that already contributed approximately $6.65 billion to total revenue in the 2025 fiscal year.
A Landmark Oral Treatment Regimen
The FDA’s decision grants approval for the use of Venclexta combined with Acalabrutinib as a first-line treatment for adults diagnosed with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This approval establishes the first entirely oral, fixed-duration treatment plan for this patient group, consisting of 14 cycles. Crucially, it eliminates the need for indefinite, lifelong therapy that has characterized previous standard approaches.
The regulatory clearance is supported by data from the Phase 3 AMPLIFY trial. Results demonstrated that the combination therapy reduced the risk of disease progression or death by 35% compared to standard chemoimmunotherapy. While the median progression-free survival in the control group was 47.6 months, this benchmark was not yet reached in the group receiving the new combination—a strong indicator of its efficacy.
Should investors sell immediately? Or is it worth buying AbbVie?
Financial Performance and Forward Guidance
Looking ahead, AbbVie’s management has provided an optimistic adjusted earnings per share (EPS) forecast for the 2026 fiscal year, projecting a range between $14.37 and $14.57. This guidance is built upon a robust fourth-quarter performance in 2025, during which the company’s quarterly revenue increased by 10% year-over-year to $16.62 billion.
Despite the positive news flow, a degree of investor caution has been evident in recent trading activity. The stock closed Friday’s session at €191.00 and remains down nearly 2.45% since the start of the year. However, the current Relative Strength Index (RSI) reading of 16.8 points to a severely oversold condition, which may attract contrarian investors following the FDA announcement.
Dividend Consistency and Key Dates
Beyond growth catalysts from its oncology pipeline, AbbVie maintains its appeal for income-focused shareholders through a reliable dividend. The company has consistently increased its payout since becoming an independent entity in 2013. A quarterly dividend of $1.73 per share is scheduled for distribution on May 15, 2026. Investors should note April 15, 2026, as the next key date, as it will serve as the record date for eligibility to receive this upcoming payment.
Ad
AbbVie Stock: Buy or Sell?! New AbbVie Analysis from February 23 delivers the answer:
The latest AbbVie figures speak for themselves: Urgent action needed for AbbVie investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 23.
AbbVie: Buy or sell? Read more here...
